Maintain a weight loss journal or track your progress on a mobile app
Despite these setbacks, encouraging animal data warrant future efforts for the development of new drugs capable to activate synergistically both GPR40 and GPR120 and mediate, through GLP-1 and other intestinal, pancreatic and cerebral peptides, better treatments for multifactorial chronic metabolic diseases
A superior molecule with the same evidence base If a next-generation regenerative active emerged with comparable safety, broader mechanism evidence, and better intrinsic delivery, the focus would shift
Jul 16 2013;12:102
Multiple clinical trialsincluding SUSTAIN-6 (semaglutide) and REWIND (dulaglutide)showed significant reductions in major adverse cardiovascular events (MACE) such as: Heart attack Stroke Cardiovascular death This benefit appears to be independent of weight loss , suggesting direct protective effects on the arteries, blood pressure, and cholesterol metabolism
So why is Novo proving this as a subcutaneous product rather than pushing directly into oral
